Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Progress Seen In Some African HIV/AIDS Prevention, Treatment Programs, U.N. Special Envoy Says At World Economic Forum On Africa
Several African countries have successfully scaled up their HIV/AIDS prevention and treatment programs, U.N. Special Envoy for HIV and AIDS in Africa Elizabeth Mataka said during a media briefing at the World Economic Forum on Africa being held in Cape Town, South Africa, the ZANIS/Lusaka Times reports. Zambia and Botswana were among some of the countries that have made significant progress in southern Africa, according to Mataka.
generic viagra online
Varying Reductions In Breast Cancer Suggest Hormone Therapy To Blame
The recent decline in invasive breast cancer in the US was significantly less pronounced in the poor and those who live in rural areas. Researchers writing in the open access journal BMC Medicine suggest this may be due to varying reductions in the numbers of women taking hormone therapy (HT).
News of the day
Lobbying Draws On Ranks Of Former Government Officials, Health Industry Coffers
"The nation"s largest insurers, hospitals and medical groups have hired more than 350 former government staff members and retired members of Congress in hopes of influencing their old bosses and colleagues, according to an analysis of lobbying disclosures and other records," the Washington Post reports. The Post"s analysis of lobbying disclosure records shows that three-quarters of major health firms have hired an insider to lobby on their behalf; half of those insiders once worked for the key senators and congressional committees that are now shaping the reform proposals.
Endocrinology

NovImmune Successfully Completes NI-0801 Phase I Clinical Study

NovImmune, an immunology-focused biotech company dedicated to the development of therapeutic monoclonal antibodies, announced the successful completion of the first phase I clinical study with its fully human monoclonal antibody NI-0801 targeting the chemokine IP-10 (CXCL10) in healthy volunteers. The randomized, doubleblinded, placebo controlled, single centre, phase I study of escalating single intravenous doses of NI-0801 in healthy volunteers (study NI-0801-01) demonstrated that NI-0801 is well tolerated at doses up to and including 20mg/kg. Chemokines are a group of low molecular weight proteins that induce the chemotaxis of different leukocytes to sites of injury or infection. IP-10 is constitutively expressed at low levels in thymic, splenic and lymph node stroma tissues, but its expression can be induced on a variety of cell types including endothelial cells, keratinocytes, fibroblasts, monocytes and neutrophils. IP-10 not only mediates leukocyte recruitment, but also drives T-cell proliferation upon antigenic stimulation. Cell migration in response to chemoattractants requires the retention of IP-10, which is also true for all other chemokines, in the vicinity of the site of inflammation to make sure cells are recruited where they are needed. IP-10 expression at sites of inflammation, leads to local accumulation of specialized cells responsible for the inflammation process in a number of different autoimmune conditions including psoriasis, multiple sclerosis, ulcerative colitis, rheumatoid arthritis, atherosclerosis, liver fibrosis and sarcoidosis. Dr Penelope Ward, Chief Medical Officer commented that "since increased IP-10 (CXCL10) levels correlate with disease severity, an ability to neutralize its effects with a target specific monoclonal antibody offers a promising strategy for the treatment of diseases such as liver fibrosis and lupus, for which therapeutic options are currently limited." NI-0801 is well aligned within NovImmune"s overall expertise and strategy in the field of chemokines to develop potential future therapeutics. Along these lines NovImmune is very happy to have become a member of the European F6 consortium "Innovative Chemokine-based Therapeutic Strategies for Autoimmunity and Chronic Inflammation" (INNOCHEM). Dr Marie Kosco-Vilbois, CSO at NovImmune, commented that "it is a great pleasure and opportunity for NovImmune to be part of a European group of Excellence in the field of future therapeutic applications of the "chemiome", where eminent academic and industrial partners cooperate to translate chemokine biology into effective therapeutics." NovImmune SA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009